Albert Einstein College of Medicine Awarded $1 Million Challenge Gift for COVID-19 Research from the Price Family Foundation
June 2, 2020—(BRONX, NY)—Albert Einstein College of Medicine has received a $1 million challenge grant from Michael F. Price and the Price Family Foundation to support COVID-19 research. The foundation will match donations to Einstein for research on the novel coronavirus, dollar-for-dollar, up to $1 million. (Source: Einstein News)
Source: Einstein News - June 2, 2020 Category: Universities & Medical Training Source Type: news
Montefiore and Einstein Test a New Drug Combination to Conquer COVID-19
May 26, 2020—(BRONX, NY)—Montefiore Health System andAlbert Einstein College of Medicine have begun the next stage of the Adaptive COVID-19 Treatment Trial (ACTT), to evaluate treatment options for people hospitalized with severe COVID-19 infection. The new iteration of the trial, known as ACTT 2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. (Source: Einstein News)
Source: Einstein News - May 26, 2020 Category: Universities & Medical Training Source Type: news
Einstein Celebrates 62nd Commencement with Historic Virtual Ceremony
May 26, 2020—(BRONX, N.Y)—Later today,Albert Einstein College of Medicine will celebrate the Class of 2020 by holding its first-ever virtual commencement ceremony. The event will honor Einstein’s 202 graduating medical and graduate students and confer them with their well-earned degrees. (Source: Einstein News)
Source: Einstein News - May 26, 2020 Category: Universities & Medical Training Source Type: news
A Promising Drug for the Treatment of Severe Lung Inflammation in COVID-19 Patients: Montefiore-Einstein Scientists Lead Two Trials of Leronlimab
May 21, 2020—BRONX, NY—Montefiore Health System andAlbert Einstein College of Medicine are the first sites in the nation to begin evaluating an investigational drug in two separate, FDA-approved trials: one to treat mild-to-moderate cases of COVID-19 and the other to treat severely ill COVID-19 patients. They are hopeful that the drug, leronlimab, may prevent the“cytokine storm” that inflames and fatally damages the lungs and other organs of many COVID-19 patients. (Source: Einstein News)
Source: Einstein News - May 22, 2020 Category: Universities & Medical Training Source Type: news
Children Not Immune to Coronavirus: New Study from Pandemic Epicenter Describes Severe COVID-19 Response in Children
NEW YORK (May 19, 2020)— While most children infected with the novel coronavirus have mild symptoms, a subset requires hospitalization and a small number require intensive care. A new report from pediatric anesthesiologists, infectious disease specialists and pediatricians at theChildren’s Hospital at Montefiore (CHAM) and Albert Einstein College of Medicine, describes the clinical characteristics and outcomes of children hospitalized with COVID-19, during the early days of the pandemic. (Source: Einstein News)
Source: Einstein News - May 20, 2020 Category: Universities & Medical Training Source Type: news
First-Of-Its-Kind Report Details How New York Children's Hospital Transformed to Provide Care to Adult COVID-19 Patients
NEW YORK (May 4, 2020)— Over the course of two weeks in March, COVID-19 cases at Montefiore grew from two to almost 700. As the health system looked to increase capacity, an inpatient pediatric unit at theChildren’s Hospital at Montefiore (CHAM), quickly became a 40-bed unit that would be home to adult patients. A new, first-of-its-kind report published in theJournal of Pediatrics describes the rapid transformation that took place. The report also shares valuable lessons learned and best practices for healthcare providers throughout the country, who may face a similar situation in the weeks ahead. (Source: Einstein News)
Source: Einstein News - May 5, 2020 Category: Universities & Medical Training Source Type: news
Cancer Patients Face High Mortality from COVID-19
May 1, 2020—(BRONX, NY)—People with cancer who develop COVID-19 are much more likely to die from the disease than those without cancer, according to physician-researchers atMontefiore Health System andAlbert Einstein College of Medicine. The study, published today in the online edition of Cancer Discovery, is the largest so far to assess outcomes for patients with cancer who have also been infected with COVID-19. (Source: Einstein News)
Source: Einstein News - May 1, 2020 Category: Universities & Medical Training Source Type: news
Trial of Highly Touted Drug Begins at Montefiore and Einstein
(BRONX, NY)—April 29, 2020—Researchers atMontefiore Health System andAlbert Einstein College of Medicine have begun testing the drughydroxychloroquine for the treatment of COVID-19, as part of a nationwide trial sponsored by the National Heart, Lung, and Blood Institute (NHLBI). (Source: Einstein News)
Source: Einstein News - April 29, 2020 Category: Universities & Medical Training Source Type: news
Clinical Trial Begins to See if Convalescent Plasma Can Treat COVID-19
April 29, 2020—(BRONX, NY)—Montefiore Health System,Albert Einstein College of Medicine and NYU Langone have launched a new clinical trial to study if convalescent plasma—taken from people who have recovered from COVID-19—is effective in treating the disease. (Source: Einstein News)
Source: Einstein News - April 29, 2020 Category: Universities & Medical Training Source Type: news
Einstein-Invented Compound Now Being Tested in COVID-19 Clinical Trial
April 28, 2020—(BRONX, NY)—A compound originally discovered byAlbert Einstein College of Medicine’sVern Schramm, Ph.D., is being evaluated by BioCryst Pharmaceuticals, Inc., in Brazil as a treatment for COVID-19 patients. The randomized, double-blind, placebo-controlled trial is funded by the National Institute of Allergy and Infectious Diseases. (Source: Einstein News)
Source: Einstein News - April 28, 2020 Category: Universities & Medical Training Source Type: news
Albert Einstein College of Medicine Holds Early Graduation to Help Confront COVID-19 Pandemic
April 17, 2020—(BRONX, NY)—Answering the call for additional medical workers to join the frontlines of the COVID-19 pandemic, today more than 100 medical students atAlbert Einstein College of Medicine graduated a month early. Many of these newly minted doctors will immediately join the staff of hospitals in New York City, contributing to the heroic efforts of medical teams who are treating patients fighting this devastating disease. (Source: Einstein News)
Source: Einstein News - April 17, 2020 Category: Universities & Medical Training Source Type: news
Slower Clearance of Coronavirus Infection May Explain Why Men Fare Worse Than Women
(BRONX, NY)—April 17, 2020—Researchers atMontefiore Health System andAlbert Einstein College of Medicine may have solved a mystery surrounding the novel coronavirus pandemic: Why men infected by the virus generally show more severe symptoms and are more likely than women to die from COVID-19. In collaboration with the Kasturba Hospital for Infectious Diseases in Mumbai, India, the scientists showed for the first time that men clear the virus from their bodies slower than women and found a possible explanation: a potential male-only“reservoir” for coronavirus. (Source: Einstein News)
Source: Einstein News - April 17, 2020 Category: Universities & Medical Training Source Type: news
Einstein Announces Early Graduation to Help Fight the COVID-19 Pandemic
Yesterday, Albert Einstein College of Medicine informed members of the class of 2020 that they may choose to graduate early, on Friday, April 17, if they have completed their curricular requirements. This voluntary opportunity was offered in order to provide support to hospitals as they continue to manage the surge of COVID-19 patients in New York City and beyond. Students also may choose to graduate on the original date of May 26. (Source: Einstein News)
Source: Einstein News - April 10, 2020 Category: Universities & Medical Training Source Type: news
Montefiore and Einstein Begin Clinical Trial for Severely Ill COVID-19 Patients
(BRONX, NY)—April 3, 2020—Montefiore Health System andAlbert Einstein College of Medicine has started treating very sick COVID-19 patients as part of a multicenter trial evaluating a potential therapy for the new disease. The double-blind, placebo-controlled trial is testing whether sarilumab, a drug already approved for treating rheumatoid arthritis, can halt the inflammation that can overwhelm the lungs of COVID-19 patients. A very similar drug yielded promising results in a recent study involving patients in China. (Source: Einstein News)
Source: Einstein News - April 3, 2020 Category: Universities & Medical Training Source Type: news
Clinical Trial for Severely Ill COVID-19 Patients Now Underway at Montefiore-Einstein
(BRONX, NY)—April 3, 2020—Montefiore Health System andAlbert Einstein College of Medicine has started treating very sick COVID-19 patients as part of a multicenter trial evaluating a potential therapy for the new disease. The double-blind, placebo-controlled trial is testing whether sarilumab, a drug already approved for treating rheumatoid arthritis, can halt the inflammation that can overwhelm the lungs of COVID-19 patients. A very similar drug yielded promising results in a recent study involving patients in China. (Source: Einstein News)
Source: Einstein News - April 3, 2020 Category: Universities & Medical Training Source Type: news
